Morepen Laboratories Ltd (MOREPENLAB) is currently trading at 113.70 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Morepen Laboratories Limited is an India-based pharmaceutical manufacturer focused on APIs, CDMO services, finished formulations, medical devices, and healthcare products, supported by manufacturing facilities in Himachal Pradesh and a research centre. Its portfolio includes globally supplied APIs, therapeutic formulations, glucose and blood-pressure monitoring devices, and emerging chronic-care products. The company delivered a sharp earnings inflection in Q2 FY27, with revenue rising 81% year over year to Rs. 755 crore, EBITDA increasing 273% to Rs. 132 crore, and PAT growing 117% to Rs. 89 crore. EBITDA margin expanded to 17.45%, suggesting that mix improvement and operating leverage are becoming financially visible. CDMO has moved from strategic promise to material commercial contribution. Q2 CDMO revenue reached Rs. 253 crore versus Rs. 58 crore in Q1, while the business reported an Rs. 825 crore global mandate and H1 CDMO revenue of Rs. 311 crore, materially increasing the importance of longer-duration, higher-value manufacturing programmes. Morepen’s revenue base is becoming substantially more global, with H1 export revenue rising 122% year over year to Rs. 654 crore and reaching approximately half of sales, compared with 35% previously. Around 76% of API revenue comes from exports, increasing access to global opportunities but also exposure to regulatory, currency, and customer-concentration risks. Medical devices provide a scalable chronic-care platform alongside APIs and CDMO. The company reports approximately 20 million meters installed and annual consumables of roughly 500 million strips, while Q2 device revenue grew 65% to Rs. 208 crore, supported by all-India distribution, service infrastructure, and backward-integrated manufacturing.

Over the past 52 weeks, Morepen Laboratories Ltd has traded between a low of ₹33.44 and a high of ₹150.80. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Morepen Laboratories Ltd has a market capitalization of approximately 6,556.27. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Morepen Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 34.79 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 6,556.27 Cr, Morepen Laboratories Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Morepen Laboratories Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Morepen Laboratories Ltd is 34.79. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Morepen Laboratories’ board is scheduled to consider and approve Q2 FY27 and half-year FY27 results on October 27, 2026.

The court granted a stay on the operation of the ₹117.94 crore GST show-cause notice, temporarily preventing enforcement while legal proceedings continue.

The Board of Directors meeting is scheduled for August 4, 2026 to consider and approve Q1 FY27 results.

Morepen said the CDMO mandate is valued at approximately ₹825 crore, also reported as USD 91 million, from a leading global pharma major.